Open in APP

Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up

Abstract:

Background and Objectives The PARS (Parkinson Associated Risk Syndrome) study was designed to test whether screening for hyposmia followed by dopamine transporter imaging can identify risk for conversion to clinical PD, and to evaluate progression markers during the prodromal period. Methods Subjects with hyposmia completed annual clinical evaluations and biennial [123I]ß‐CIT single‐photon emission computed tomography scans. Subjects were categorized as normal (>80% age‐expected tracer uptake; n = 134), indeterminate (>65–80%; n = 30), and dopamine transporter deficit (≤65%; n = 21) by their baseline scan, and survival analysis was used to compare risk of conversion to motor PD. Progressing to a scan with a dopamine transporter deficit was assessed for those subjects with either normal or indeterminate baseline imaging. Results Over a mean of 6.3 [standard deviation: 2.2] years of follow‐up, 67% (n = 14) of dopamine transporter deficit subjects, 20% (n = 6) of dopamine transporter indeterminate subjects, and 4% (n = 6) of dopamine transporter normal subjects converted to a PD diagnosis (P < 0.0001). Among subjects without dopamine transporter deficit at baseline, a reduction to ≤65% age‐expected uptake occurred in 12 of 30 (40%) with indeterminate dopamine transporter and 7 of 134 (5%) with no dopamine transporter DAT deficit (P < 0.0001). Imaging conversion during follow‐up was associated with subsequent clinical conversion (hazard ratio: 9.6; P = 0.0157). Discussion and Conclusions Long‐term follow‐up of the PARS cohort demonstrated a high rate of conversion to clinical PD in subjects who either had abnormal dopamine transporter imaging at baseline or developed abnormal imaging during follow‐up. These data extend the earlier PARS findings and present new results showing the sequence of incident imaging deficit, imaging progression, and clinical changes that occur in prodromal PD. © 2020 International Parkinson and Movement Disorder Society

Keywords: biomarkers, dopamine transporter imaging, Parkinson's disease, prodromal

Author: Andrew Siderowf, Danna Jennings, Matthew Stern, John Seibyl, Shirley Eberly, David Oakes, Kenneth Marek,
Journal: Movement Disorders( IF:8.1 )   Time:2020-09-16
DOI:10.1002/mds.28139    [Quote]
Link:     Article     PDF


Comments    Read:5

Ftracker is a frontier tracker.
专业学术信息平台,免费并及时为您提供全球范围内各大期刊的最新学术信息。 “关键词内容订制”,”期刊浏览”,”数据库检索”,”期刊下载”,”评论讨论”。
Mobile App
Android(Download)
(微信浏览器不支持文件下载,请右上角用浏览器打开。)
IOS search "Ftracker" in AppStore
学术交流QQ群
Ftracker学术犬: 970207982

文献求助群Ftracker: 698420805

新冠病毒交流Ftracker: 878107029

植物基因功能Ftracker: 556178713

©2020 Ftracker

微信打开×